IP Library › Granted Patent US 12,378,522
Granted Patent B2
US 12,378,522 · App. 18/132,713 · Granted Aug 5, 2025

Cell therapy compositions and methods of use thereof

Inventors: Edmund Sullivan (Bellingham, WA); Theresa Westfall (Bellingham, WA)
Assignee: AURELIUS BIOTHERAPEUTICS, LLC
C12N5/0639A61K31/475A61K31/519A61K31/573A61K31/675A61K31/704A61K38/177A61K38/50A61K40/11A61K40/4211A61K40/4221A61K40/4224A61K40/4234A61K45/06A61N5/10A61P35/00C12N5/0636C12Y305/01001A61K2035/124A61K2239/31A61K2239/38A61K2239/48C12N2501/2302C12N2501/2321C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,522
App. No.
18/132,713
Granted
Aug 5, 2025
Kind
B2
Abstract

The present disclosure provides compositions of immune cells presenting a target molecule or a fragment thereof and provides compositions and methods of producing immune cell therapies with targeted activity against cancer. Methods for conditioning a subject receiving the immune cell therapy of the disclosure are additionally disclosed. The immune cell therapies of the present disclosure can be administered to a subject in need thereof for diseases such as cancer.

Claims (15)

1. A composition for treating a canine or a feline animal in need thereof, wherein the composition comprises a modified CD20 antigen specific cell primed by a cell presenting a recombinant CD20 or an antigenic fragment thereof, wherein the composition comprises at least 1.55×10 5 modified CD20 antigen specific cells/kg recipient weight, wherein the modified CD20 antigen specific cell is a propagated T cell.

2. The composition of claim 1 , wherein the propagated T cell expresses CD5, CD8 and CD4.

3. The composition of claim 2 , wherein the composition comprises a CD4: CD8 ratio of less than 1.

4. The composition of claim 2 , wherein the composition comprises a CD4: CD8 ratio of 16:33.

5. The composition of claim 2 , wherein the composition comprises a CD4: CD8 ratio of 18:33.

6. The composition of claim 1 , wherein the propagated T cell is propagated ex vivo.

7. The composition of claim 1 , wherein the recombinant CD20 or the antigenic fragment thereof comprises a canine CD20 or an antigenic fragment thereof.

8. The composition of claim 7 , wherein the canine CD20 or the antigenic fragment thereof comprises at least 80% sequence identity to SEQ ID NO: 1.

9. The composition of claim 8 , wherein the canine CD20 or the antigenic fragment thereof comprises SEQ ID NO: 1.

10. The composition of claim 1 , wherein the recombinant CD20 or the antigenic fragment thereof comprises a feline CD20 or an antigenic fragment thereof.

11. The composition of claim 10 , wherein the feline CD20 or the antigenic fragment thereof comprises at least 80% sequence identity to SEQ ID NO: 3.

12. The composition of claim 11 , wherein the feline CD20 or the antigenic fragment thereof comprises SEQ ID NO: 3.

13. The composition of claim 1 , wherein the composition comprises 1.55×10 5 modified CD20 antigen specific cells/kg recipient weight to 3.67×10 7 modified CD20 antigen specific cells/kg recipient weight.

14. The composition of claim 13 , wherein the composition comprises 1.5×10 6 modified CD20 antigen specific cells/kg recipient weight to 1.65×10 7 modified CD20 antigen specific cells/kg recipient weight.

15. The composition of claim 13 , wherein the composition comprises 3.35×10 5 modified CD20 antigen specific cells/kg recipient weight to 2.51×10 7 modified CD20 antigen specific cell/kg recipient weight.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2023
From: SULLIVAN, EDMUND; WESTFALL, THERESA
To: AURELIUS BIOTHERAPEUTICS, LLC
Reel/Frame 063804/0185 →
Continuity (3)
Continuation 16320729
Provisional Application 62373243 · Aug 10, 2016
Related Publication 20230372392A1 · Nov 23, 2023
References Cited (52)
US 7531628B2 · Beall · 2009 [cited by applicant]
US 11648265B2 · Sullivan et al. · 2023 [cited by applicant]
US 20050048071A1 · Bae et al. · 2005 [cited by applicant]
US 20050271662A1 · Beall et al. · 2005 [cited by applicant]
US 20060017950A1 · Ikegami et al. · 2006 [cited by applicant]
US 20060269973A1 · Yee · 2006 [cited by applicant]
US 20100136558A1 · Kano et al. · 2010 [cited by applicant]
US 20110217298A1 · Hansen et al. · 2011 [cited by applicant]
US 20120321666A1 · Cooper et al. · 2012 [cited by applicant]
US 20130183343A1 · Czerniecki et al. · 2013 [cited by applicant]
US 20140316125A1 · Ferrand et al. · 2014 [cited by applicant]
US 20190151359A1 · Sullivan et al. · 2019 [cited by applicant]
EP 3497243A1 · 2019 [cited by applicant]
WO WO2016201394A1 · 2016 [cited by applicant]
WO WO2018031811A1 · 2018 [cited by applicant]
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharma 2016;7:27-31. (Year: 2016). [cited by examiner]
Ahuja et al.: Depletion of B Cells in Murine Lupus: Efficacy and Resistance. J Immunol 179(5):3351-3361 (2007). https://doi.org/10.4049/jimmunol.179.5.3351. [cited by applicant]
Panjwani et al.: Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Mol Ther. 24(9):1602-14 (2016). doi: 10.1038/mt.2016.146. Epub Jul. 12… [cited by applicant]
Addissie, et al. Cellular Immunotherapy of Canine Cancer. Veterinary sciences 5.4 (Dec. 6, 2018): 100. 8 pages. [cited by applicant]
Appelbaum, et al. Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. Transplantation 42.1 (Jul. 1986): 19-22. [cited by applicant]
Bae et al.: Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies. Clin Cancer Res. 11(4): 1629-1638 (2005). [cited by applicant]
Bujak, et al. Adoptive cell transfer: new perspective treatment in veterinary oncology. Acta veterinaria scandinavica 60.1 (Oct. 18, 2018): 60. 13 pages. [cited by applicant]
Deeg, et al. Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation. American journal of veterinary research 46.9 (1985): 2016… [cited by applicant]
EP Application No. 17840300.2 Communication pursuant to Article 94(3) EPC mailed Oct. 14, 2021. [cited by applicant]
European Patent Application No. 17840300.2 Supplementary European Search Report dated Mar. 4, 2020. [cited by applicant]
Frimberger, et al. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. Journal of veterinary internal medicine 20.2 (2006): 355-364. [cited by applicant]
Hudecek, et al. Adoptive T-cell therapy for B-cell malignancies. Expert review of hematology 2.5 (Oct. 2009): 517-532. [cited by applicant]
International search report with written opinion dated Nov. 21, 2017 for PCT/US17/46354. [cited by applicant]
Kano, et al. Canine CD20 gene. Veterinary immunology and immunopathology 108.3-4 (2005): 265-268. [cited by applicant]
Klingenmann, H. Immunotherapy for dogs: running behind humans. Frontiers in Immunology9 (Feb. 5, 2018): 133. 6 Pages. [cited by applicant]
Lupu, et al. Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model. Veterinary and comparative oncology 5.1 (Mar. 2007): 14-30. [cited by applicant]
Lupu, et al. Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. Journal of the American Veterinary Medical Association 22… [cited by applicant]
Marconato, L. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. The Veterinary Journal 188.1 (2011): 34-38. [cited by applicant]
Marconato, L. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. The Veterinary Journal 188.1 (Apr. 2011): 34-38. [cited by applicant]
Mata, et al. Towards immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. Journal of immunotherapy (Hagerstown, Md.: 1997) 37.8 (2014)… [cited by applicant]
Mie, et al. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection. Veterinary immunology and immunopathol… [cited by applicant]
Oconnor, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Scientific reports 2 (Feb. 13, 2012): 249. 12 pages. [cited by applicant]
O'Connor, et al. Developing T cell cancer immunotherapy in the dog with lymphoma. ILAR journal 55.1 (2014): 169-181. [cited by applicant]
Panjwani, M.K. et al., Feasability and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma, Molecular Therapy, 2016, vol. 24, No. 9, pp. 1602-1614. [cited by applicant]
PCT/US17/46354 International Search Report mailed Nov. 21, 2017. [cited by applicant]
PCT/US2017/046354 International Preliminary Report on Patentability mailed Feb. 12, 2019. [cited by applicant]
Redeker, A. et al., “The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination”, Frontiers in Immunology, 2016, vol. 7, Article 345, pp. 1-17. [cited by applicant]
Redeker et al.: Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Front Immunol. 7(345): 1-17 (2016). [cited by applicant]
Richards, et al. Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?. Immunological reviews263.1 (2015): 173-191. [cited by applicant]
Schnurr et al., Tumor Cell Lystate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines. Cancer Research 61: 6445-6450 (2001). [cited by applicant]
Sun, et al. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. The Journal of Immunology 165.7 (2000): 4105-4111. [cited by applicant]
Suter, et al. Allogeneic hematopoietic cell transplantation in a dog with acute large granular lymphocytic leukemia. Journal of the American Veterinary Medical Association 246.9 (2015): 994-997.Partial retraction in: J … [cited by applicant]
Suter, et al. Allogeneic hematopoietic cell transplantation in a dog with acute large granular lymphocytic leukemia. Journal of the American Veterinary Medical Association 246.9 (May 1, 2015): 994-997. [cited by applicant]
Tagawa, et al. Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma. PloS one 13.7 (Jul. 24, 2018): e0201222. 14 Pages. [cited by applicant]
Wang, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Molecular Therapy 9.4 (Apr. 2004): 577-586. [cited by applicant]
Wang, X.: The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma. NIH U.S. National Library of Medicine, ClinicalTrials.gov. Study Details; Tabular View; Disclaimer:… [cited by applicant]
Waugh, et al. Optimisation and validation of a PCR for antigen receptor rearrangement (PARR) assay to detect clonality in canine lymphoid malignancies. Veterinary immunology and immunopathology 182 (2016): 115-124. [cited by applicant]